Pfizer
NEWS
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
Voyager has partnered with Novartis for the latter to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
Sanofi will more than $1 billion to build out its mRNA facilities and programs over the next several years. The site is expected to become operational in 2025.
As COVID-19 cases fall in the wake of the latest surge from the Omicron variant, the question on the minds of many is, what comes next for these Pfizer and Moderna?
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
President Biden announced updates to the “Test to Treat” initiative that will allow people to get tested for COVID at a pharmacy and receive a treatment round of Pfizer’s Paxlovid at no cost.
Pfizer announced its RSV vaccine candidate PF-06482077 or RSVpreF, received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
Throughout history, many different countries have had their biopharma supply chains changed – sometimes profitably, sometimes detrimentally – by war.
The study, which has yet to be peer-reviewed, found the Pfizer-BioNTech vaccine was only about 12% effective for children ages 5 to 11 years against the Omicron variant.
JOBS
IN THE PRESS